McKesson reorganizes into 4 segments; restates FY2025 revenue of $359B under new structure

MCKESSON CORP

Starting Q2 FY2026, McKesson will report 4 segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions.
FY2025 restated revenue: North American Pharm $304.5B, Oncology & Multispecialty $36.9B, Prescription Tech $5.2B, Medical-Surgical $11.4B; total $359.1B.
FY2025 restated adjusted op. profit: N.A. Pharm $3,145M (1.03%), Oncology & Multispecialty $936M (2.54%), Prescription Tech $961M (18.42%), Med-Surg $1,022M (8.98%).
Agreement to sell Norway operations signed Aug 4, 2025 (subject to regulatory approval); also intends to separate Medical-Surgical Solutions (announced May 2025).
Segment changes did not impact previously issued consolidated financials or EPS.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.